RxDoctor Payments Data

Shelby Thomas, NP

Family · Brandon, MSNPI 1295377877

Payments from drug & device makers

$7,464in general payments, 2019–2025

Across 421 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$630
  • Novo Nordisk$610
  • Lilly USA, LLC$451
  • AstraZeneca$383
  • Bayer$369
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$7,464100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,464 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$50,465
Medicare patients
251
Services billed
1,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$63,098
JardianceEmpagliflozin43$46,037
MounjaroTirzepatide22$27,826
FarxigaDapagliflozin Propanediol29$21,600
EliquisApixaban26$20,149
XareltoRivaroxaban12$16,973
MyrbetriqMirabegron20$14,795
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$13,059
VascepaIcosapent Ethyl14$8,353
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$7,995
LinzessLinaclotide15$7,935
SymbicortBudesonide/Formoterol Fumarate25$6,453
Incruse ElliptaUmeclidinium Bromide13$4,695
SynthroidLevothyroxine Sodium39$2,088
Valsartan109$1,827

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$610$63,09864 claims
Boehringer IngelheimJardiance$198$46,03743 claims
AstraZenecaFarxiga, Symbicort$383$28,05354 claims
Lilly USA, LLCMounjaro$451$27,82622 claims
PfizerEliquis$630$20,14926 claims
GSKTrelegy Ellipta, Incruse Ellipta$216$17,75431 claims
Johnson & JohnsonXarelto$32$16,97312 claims
Astellas Pharma US IncMyrbetriq$358$14,79520 claims
AbbVieLinzess, Synthroid$1,291$10,02454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Brandon

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →